 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Oligo Drugs Advance in the Clinic in 2012 as Delivery Hurdles are Addressed
January 03, 2013
Oligo Drugs Advance in the Clinic in 2012 as Delivery Hurdles are Addressed
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- RNAi Field Looks to Late-Stage Clinical Data, Approvals to Regain Pharma Interest
January 3, 2013 / Gene Silencing News - Former Pfizer Exec Sees Oligo Drugs Becoming Major Platform Tech in Three Years
May 24, 2012 / Gene Silencing News - As RNAi Efforts Advance, Merck Aims to Move siRNA Drug into the Clinic in 'One to Two Years'
December 8, 2011 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Alnylam; Isis; Merck; and More
February 2, 2012 / Gene Silencing News - UniQure, Collaborators Secure $3.2M Eurostar Grant for Huntington’s Disease Effort
May 23, 2013 / Gene Silencing News